共 110 条
[1]
Lanz J(2015)Stroke in adults with congenital heart disease: incidence, cumulative risk, and predictors Circulation 132 2385-2394
[2]
Brophy JM(2010)Mortality in adult congenital heart disease Eur Heart J 31 1220-1229
[3]
Therrien J(2014)Improving quality measurement for anticoagulation: adding international normalized ratio variability to percent time in therapeutic range Circ Cardiovasc Qual Outcomes 7 664-669
[4]
Kaouache M(2021)Quality and predictors of oral anticoagulation therapy with vitamin K antagonists in adult congenital heart disease: TTR and INR variability Thromb Res 207 7-9
[5]
Guo L(2022)Rate and risk factors for thromboembolism and major bleeding in adults with congenital heart disease taking vitamin K antagonist therapy Thromb Res 9 100122-1678
[6]
Marelli AJ(2020)Non-vitamin K oral anticoagulants in adults with congenital heart disease: a systematic review J Clin Med 9 1794-1100
[7]
Verheugt CL(2016)2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS Europace 18 1609-e697
[8]
Uiterwaal CSPM(2010)A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey Chest 138 1093-298S
[9]
van der Velde ET(2019)2018 AHA/ACC guideline for the management of adults with congenital heart disease: executive summary: a report of the American College of Cardiology/American Heart Association task force on Clinical Practice Guidelines J Am Coll Cardiol 139 e637-694
[10]
Meijboom FJ(2008)Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 133 257S-547